期刊
CELL
卷 144, 期 4, 页码 566-576出版社
CELL PRESS
DOI: 10.1016/j.cell.2011.01.013
关键词
-
资金
- DFG [DO 545/2-1]
- EU [LSHB-CT-019067]
- Centre for Biomolecular Magnetic Resonance (BMRZ)
- Cluster of Excellence Frankfurt (Macromolecular Complexes)
- ANR
- ERC
- Boehringer Ingelheim Fonds PhD Fellowship
- Canadian Institutes for Health Research [1097737]
- Canadian Foundation for Innovation
- Genome Canada through the Ontario Genomics Institute
- GlaxoSmithKline
- Karolinska Institutet
- Knut and Alice Wallenberg Foundation
- Ontario Innovation Trust
- Ontario Ministry for Research and Innovation
- Merck Co., Inc.
- Novartis Research Foundation
- Swedish Agency for Innovation Systems
- Swedish Foundation for Strategic Research
- Wellcome Trust
TAp63 alpha, a homolog of the p53 tumor suppressor, is a quality control factor in the female germline. Remarkably, already undamaged oocytes express high levels of the protein, suggesting that TAp63 alpha's activity is under tight control of an inhibitory mechanism. Biochemical studies have proposed that inhibition requires the C-terminal transactivation inhibitory domain. However, the structural mechanism of TAp63 alpha inhibition remains unknown. Here, we show that TAp63 alpha is kept in an inactive dimeric state. We reveal that relief of inhibition leads to tetramer formation with similar to 20-fold higher DNA affinity. In vivo, phosphorylation-triggered tetramerization of TAp63 alpha is not reversible by dephosphorylation. Furthermore, we show that a helix in the oligomerization domain of p63 is crucial for tetramer stabilization and competes with the transactivation domain for the same binding site. Our results demonstrate how TAp63 alpha is inhibited by complex domain-domain interactions that provide the basis for regulating quality control in oocytes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据